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To the editor
We read with interest the well-conducted analysis pre-
sented by Friedrichson et al. on the provision of ECMO 
in Germany from 2007 to 2018 [1].
The authors note that by 2018, there were 231 centres 
in Germany providing veno-venous ECMO support (VV-
ECMO), with a median case volume of 4 patients per year; 
70% of centres reported 10 or fewer cases annually. In the 
United Kingdom, since 2011, ECMO for respiratory fail-
ure has been provided by six centres in a hub-and-spoke 
network [2], similar to that the authors propose. We esti-
mate from the data provided that in 2018, Germany had 
one VV-ECMO centre per 358,000 head of population; in 
the UK this figure was one per 11 million [3]. Our recent 
analysis of the first six years of this service demonstrated 
a median annual case volume of 37.5 patients per centre 
and overall ICU mortality of 26% [2].
There are likely multiple factors explaining the dis-
crepancy between the UK data and the hospital mor-
tality of 54% reported by Friedrichson et  al. [1]. Firstly, 
even including neonatal and paediatric patients, 70% of 
patients receiving VV-ECMO in the German study were 
aged above 50; for the UK dataset, the corresponding 
figure was 33%. As the authors state, age is a key prog-
nostic indicator for outcome [4]. The authors analysed 
patients who received VV-ECMO with or without ARDS, 
reporting essentially identical mortality, and conclude 
that some of these patients may not have had an indi-
cation for ECMO support. We would suggest that the 
underlying pathophysiology may be more important than 
simply meeting definition criteria of ARDS. In our study, 
patients with certain underlying pathologies, such as 
asthma, were more likely to survive [2].
Although a lower short-term mortality per se does not 
necessarily mean a ‘better’ system, the benefit of expe-
rienced multidisciplinary teams—which include nurs-
ing, perfusion and therapy staff—concentrated in higher 
volume ECMO centres, is in our view inarguable. This 
experience does not just improve care for the individual 
patient, but also informs on patient selection, which is 
key to driving better outcomes. Furthermore, a central-
ised network with a single governance structure provides 
further advantages on equity of access and sharing best 
practice. For the above reasons, we would entirely agree 
with the authors’ conclusions that ‘treatment in special-
ised centres clearly results in reduced mortality.’
Yours sincerely,
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To the editor
We would like to thank Drs. Warren et al. for their valu-
able letter, which underlines the impact of our recently 
published manuscript regarding ECMO therapy in 
Germany.
Data and especially the clinical setting published by 
Warren et al. are indeed completely contrary to the situ-
ation in Germany [5]. In addition to the lower number of 
centres in England compared to Germany, there is also a 
significantly lower ECMO incidence rate of approx. 3.05 
per 1 million population compared to 18.28 per 1 million 
population [6]. Whether this clear difference is solely due 
to a different indication, e.g. inclusion of older patients, 
remains to be answered by further studies.
We agree with Warren et  al. that a consideration of 
the underlying pathophysiology in acute respiratory syn-
drome (ARDS) makes an important difference in therapy 
and prognosis. Especially the mortality rates in H1N1 
patients treated with ECMO have been shown to be 
lower than in other ARDS patients treated with ECMO 
[7]. The clinical entity of ARDS has multiple causes and 
is therefore particularly difficult to address in guidelines 
[8]. Currently, the final stage of the disease, i.e. refractory 
hypoxaemia, and its graduation, as well as the clinical 
course are the basic parameters used for ECMO indica-
tion. For this very reason, we are convinced that a cen-
tre formation with the experience, not only with regard 
to the interprofessional team, but also with regard to 
the underlying pathophysiology, can lead to a significant 
reduction in mortality. Analysing the underlying disease 
of ARDS is an important aspect; however, this was not 
possible due to the available data set of the Federal Sta-
tistical Office. We are convinced that a national registry 
for all ECLS treatments, as established in the United 
Kingdom, would be desirable for Germany. With the 
introduction of the German Interdisciplinary Association 
for Intensive and Emergency Medicine (DIVI) ECMO 
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